AIM: To evaluate the impact of hepatitis C virus (HCV) infection with genotype 1 or 3 and the presence or absence of liver cirrhosis (LC) in the early viral kinetics response to treatment. METHODS: Naive patients (n = 46) treated with interferon-alpha (IFN-alpha) and ribavirin and followed up with frequent early HCV-RNA determinations were analysed. Patients were infected with genotype 1 (n = 28, 7 with LC) or 3 (n = 18, 5 with LC). RESULTS: The first phase decline was larger in genotype 3 patients than in genotype 1 patients (1.72 vs 0.95 log IU/mL, P < 0.001). The second phase slope decline was also larger in genotype 3 patients than in genotype 1 patients (0.87 vs 0.15 log/wk, P < 0.001). Differences were found in both cirrhotic and non-cirrhotic patients. Genotype 1 cirrhotic patients had a slower 2nd phase slope than non-cirrhotic patients (0.06 vs 0.18 log/wk, P < 0.02). None of genotype 1 cirrhotic patients had a 1st phase decline larger than 1 log (non-cirrhotic patients: 55%, P < 0.02). A similar trend toward a slower 2nd phase slope was observed in genotype 3 cirrhotic patients but the 1st phase slope decline was not different. Sustained viral response was higher in genotype 3 patients than in genotype 1 patients (72% vs 14%, P < 0.001) and in genotype 1 non-cirrhotic patients than in genotype 1 cirrhotic patients (19% vs 0%). A second phase decline slower than 0.3 log/wk was predictive of non-response in all groups. CONCLUSION: Genotype 3 has faster early viral decline than genotype 1. Cirrhosis correlates with a slower 2nd phase decline and possibly with a lower 1st phase slope decline in genotype 1 patients.
AIM: To evaluate the impact of hepatitis C virus (HCV) infection with genotype 1 or 3 and the presence or absence of liver cirrhosis (LC) in the early viral kinetics response to treatment. METHODS: Naive patients (n = 46) treated with interferon-alpha (IFN-alpha) and ribavirin and followed up with frequent early HCV-RNA determinations were analysed. Patients were infected with genotype 1 (n = 28, 7 with LC) or 3 (n = 18, 5 with LC). RESULTS: The first phase decline was larger in genotype 3 patients than in genotype 1 patients (1.72 vs 0.95 log IU/mL, P < 0.001). The second phase slope decline was also larger in genotype 3 patients than in genotype 1 patients (0.87 vs 0.15 log/wk, P < 0.001). Differences were found in both cirrhotic and non-cirrhotic patients. Genotype 1 cirrhotic patients had a slower 2nd phase slope than non-cirrhotic patients (0.06 vs 0.18 log/wk, P < 0.02). None of genotype 1 cirrhotic patients had a 1st phase decline larger than 1 log (non-cirrhotic patients: 55%, P < 0.02). A similar trend toward a slower 2nd phase slope was observed in genotype 3 cirrhotic patients but the 1st phase slope decline was not different. Sustained viral response was higher in genotype 3 patients than in genotype 1 patients (72% vs 14%, P < 0.001) and in genotype 1 non-cirrhotic patients than in genotype 1 cirrhotic patients (19% vs 0%). A second phase decline slower than 0.3 log/wk was predictive of non-response in all groups. CONCLUSION: Genotype 3 has faster early viral decline than genotype 1. Cirrhosis correlates with a slower 2nd phase decline and possibly with a lower 1st phase slope decline in genotype 1 patients.
Authors: F Torre; R Giusto; A Grasso; R Brizzolara; N Campo; N Sinelli; V Balestra; A Picciotto Journal: J Med Virol Date: 2001-08 Impact factor: 2.327
Authors: S Zeuzem; E Herrmann; J H Lee; J Fricke; A U Neumann; M Modi; G Colucci; W K Roth Journal: Gastroenterology Date: 2001-05 Impact factor: 22.682
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Thomas J Layden; Jennifer E Layden; K Rajender Reddy; Rachel S Levy-Drummer; Jennifer Poulakos; Avidan U Neumann Journal: J Viral Hepat Date: 2002-09 Impact factor: 3.728
Authors: Jennifer E Layden; Thomas J Layden; K Rajender Reddy; Rachel S Levy-Drummer; Jennifer Poulakos; Avidan U Neumann Journal: J Viral Hepat Date: 2002-09 Impact factor: 3.728
Authors: Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: T Asselah; N Boyer; M-C Guimont; D Cazals-Hatem; F Tubach; K Nahon; H Daïkha; D Vidaud; M Martinot; M Vidaud; C Degott; D Valla; P Marcellin Journal: Gut Date: 2003-11 Impact factor: 23.059
Authors: Stephanie T Shi; Stephen J Polyak; Hong Tu; Deborah R Taylor; David R Gretch; Michael M C Lai Journal: Virology Date: 2002-01-20 Impact factor: 3.616
Authors: E S A Araújo; H Dahari; A U Neumann; N de Paula Cavalheiro; C E Melo; E S de Melo; T J Layden; S J Cotler; A A Barone Journal: J Viral Hepat Date: 2011-04 Impact factor: 3.728
Authors: Jannick Verbeeck; Mark J Stanley; Jen Shieh; Linda Celis; Els Huyck; Elke Wollants; Judy Morimoto; Alice Farrior; Erwin Sablon; Margaret Jankowski-Hennig; Carl Schaper; Pamela Johnson; Marc Van Ranst; Marianne Van Brussel Journal: J Clin Microbiol Date: 2008-04-09 Impact factor: 5.948
Authors: Harel Dahari; Jennifer E Layden-Almer; Eric Kallwitz; Ruy M Ribeiro; Scott J Cotler; Thomas J Layden; Alan S Perelson Journal: Gastroenterology Date: 2009-01-01 Impact factor: 22.682